EQ (Equillium) Tariff Resilience Score: 6/10 (As of Jul. 04, 2026)


EQ Equillium Inc EQ
28 GF Score
Price $2.91
GF Value $0.10
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Equillium Tariff Resilience Score?

Equillium EQ -3.64% 28 Tariff Resilience Score is 6 as of Jul. 04, 2026. GuruFocus rates EQ with a GF Score™ of 28/100 and a GF Value™ of $0.10 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,373 Biotechnology companies, Equillium ranks better than 75.97% on this metric.

Equillium has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Equillium has Equillium Inc operates in the biotech sector, which is less affected by tariffs. However, it relies on international partnerships for research and development. The company has some pricing power and can adjust strategies to mitigate tariff impacts.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Equillium might have Average Resilient.

Equillium  (NAS:EQ) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Equillium Tariff Resilience Score Related Terms

EQ vs ORMP, HUMA, NBP: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Equillium's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Equillium Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Equillium's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Equillium's Tariff Resilience Score falls into.


EQ
28GF Score
Equillium Inc EQ
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Equillium (EQ) has a Tariff Resilience Score of 6 as of Jul. 04, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Equillium ranks #330 out of 1373 companies in the Biotechnology industry, placing it in the top 24%.
Is Equillium's Tariff Resilience Score too high?
Equillium's current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. Equillium's value of 6 is 50% above this industry median. Based on the distribution chart, Equillium ranks #330 out of 1373 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Equillium has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Equillium's Tariff Resilience Score compare to ORMP and HUMA?
According to the Biotechnology industry distribution chart, Equillium ranks #330 out of 1373 companies for Tariff Resilience Score. This places Equillium in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Equillium's value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,373 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Equillium's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Equillium's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Equillium stock overvalued right now?
Based on GuruFocus' analysis, Equillium (EQ) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.10, compared to a current price of $2.91 — trading 2810% above its estimated fair value. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. Equillium's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Equillium (EQ), the current Tariff Resilience Score is 6 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Equillium (EQ) Overvalued in 2026?

Based on GuruFocus' analysis, Equillium stock appears to be overvalued. The current stock price of $2.91 is trading 2810% above its estimated GF Value™ of $0.10. GuruFocus considers Equillium to be Significantly Overvalued.

Key valuation signals for EQ:

  • Tariff Resilience Score: 6
  • GF Value™: $0.10 vs. price of $2.91 (2810% above fair value)
  • GF Score™: 28/100 with 3 warning signs
  • Industry Position: 50% above the Biotechnology median (#330 of 1373)

No single metric tells the full story. See the EQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Equillium Business Description

Other Exchanges 0A4D:UK0FY:Germany
Address 2223 Avenida De La Playa, Suite 105, La Jolla, CA, USA, 92037
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.
28GF Score

Get the complete analysis for EQ

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.91
Price
$0.10
GF Value